The 15 mg Mounjaro Pen: Mounjaro's Highest Dose Explained

Why does a 15 mg dose exist if lower doses already work?

Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1) involved in appetite regulation and blood-sugar control. The dose schedule exists not because lower strengths are failures, but because people respond differently. Some reach a meaningful plateau at 5 mg or 10 mg; others need the full 15 mg to get the results that matter to their health. Mounjaro's licensed UK strengths run from 2.5 mg through to 15 mg in six steps, and the titration is designed to be slow enough that your body can adapt at each level before moving on.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, compared all three therapeutic doses across 2,539 adults with obesity. The 15 mg group achieved the largest average weight reduction (around 20–21% of starting body weight over 72 weeks) compared with roughly 15% at the 5 mg Mounjaro pen and 19% at the 10 mg Mounjaro pen. That gap matters clinically for people who have not hit their target on a lower dose. It is also worth saying plainly: some people do reach their clinical goals well before 15 mg, and staying at a lower dose that is working well is entirely reasonable.

You can read a full overview of tirzepatide on the NHS tirzepatide medicines page, which covers how it works, its licensed uses and what to discuss with your prescriber.

Who is likely to reach the 15 mg Mounjaro pen, and how long does it take?

Most people who reach 15 mg do so after working steadily through the preceding doses, typically spending at least four weeks at each strength before a prescriber considers moving up. From the 2.5 mg starting pen to the 15 mg pen, the minimum titration period under the licensed schedule is around five months, though many people take longer, particularly if they have had episodes of nausea or other side effects that prompted a pause.

Reaching 15 mg is not guaranteed or automatic. A prescriber looks at more than the calendar: how much weight you have lost, how well you have tolerated each previous dose, and whether there are any clinical reasons to hold at a lower strength. If you started on the 2.5 mg starter pen and have been titrating steadily, your prescriber will review evidence of your progress before confirming the step to 15 mg.

It is worth being honest with yourself and your prescriber about side effects at each stage. Moving up before your body is ready tends to make tolerability worse, not better, and there is no clinical prize for reaching the top dose quickly.

If you are curious about the cost context as doses increase, our overview of Mounjaro UK pricing changes explains the background, including how Eli Lilly's 2025 price adjustment affects private prescriptions across the dose range.

What side effects are more likely at 15 mg, and when should you contact someone?

The side-effect profile of the 15 mg Mounjaro pen is qualitatively the same as at lower doses (predominantly gastrointestinal) but intensity can increase with each dose step. Nausea, loose stools, constipation, acid reflux and reduced appetite are all common, and they tend to peak in the first week or two after a dose increase before settling. Fatigue and mild dizziness are also reported. Most people who reach 15 mg have already experienced these effects at lower doses and know roughly what to expect.

A few symptoms need prompt medical attention. Severe, persistent stomach pain that radiates to the back, with or without vomiting, requires urgent assessment because it can indicate acute pancreatitis, a known but infrequent side effect flagged in the MHRA's January 2026 Drug Safety Update for GLP-1 medicines. Signs of a serious allergic reaction, significant dehydration from prolonged vomiting or diarrhoea, and gallbladder symptoms should also not be waited out. If you are unsure whether what you are experiencing needs urgent attention, contact your prescriber or call 111 rather than guessing.

You can report any suspected side effect directly to the MHRA through the Yellow Card scheme, which helps regulators monitor emerging safety signals across all medicines. Your prescriber can also help you distinguish expected adjustment effects from something that warrants changing course.

What happens after 15 mg, is there anywhere further to go?

In the UK, 15 mg is the ceiling for tirzepatide. There is no licensed dose above it, and no clinical basis for a prescriber to go higher. If you have reached 15 mg and your weight loss has slowed or stopped, the right conversation is with your prescriber about what that means for continuing treatment, rather than assuming more medicine is the answer.

It is also genuinely worth knowing that some people who felt stuck at 10 mg found 15 mg made a significant difference, while others found the gap smaller than expected. Individual response to tirzepatide varies considerably, and clinical guidance from NICE (TA1026) suggests reviewing continuation if less than 5% weight loss has been achieved after six months at the highest tolerated dose.

If you have been wondering whether tirzepatide at any dose is the right option for you, our Mounjaro overview sets out the full picture, or you can start a free consultation and have a GPhC-registered prescriber review your situation directly. There is no obligation, and the review happens the same day.